FDA accepts Salix’s latest new drug application

Salix Pharmaceuticals announced this week that the Food and Drug Administration has accepted its new drug application for Budesonide, a rectal foam used to treat patients with ulcerative colitis.

The FDA expects to issue a ruling on the application on Sept. 15.

Raleigh-based Salix sells drugs to treat gastrointestinal ailments. Earlier this year, Salix completed its $2.6 billion acquisition of the specialty drug company Santarus, which focuses on similar areas of treatment.

Staff writer David Bracken